CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its generic version of AstraZeneca’s PARP inhibitor Lynparza (olaparib). This marks CSPC Pharmaceutical’s entry into the segment with the third generic version of Lynparza to be approved in China.
The orally administered PARP inhibitor is indicated for the treatment of patients with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, offering a new option for patients in need of such targeted therapies.- Flcube.com
